Study Finds That Insomnia Worsens Quality of Life in Adults with MDD
Major depressive disorder (“MDD”) is a medical condition that affects an individual’s behavior, mood and physical function, including sleep and appetite. This condition is sometimes referred to as clinical depression and is among the most common mental health conditions in the United States.
Insomnia is a sleep disorder that makes it hard for an individual to stay asleep, fall asleep or wake up too early. This disorder drains an individual’s mood and energy level, which affects different aspects of their lives.
A new study has found that higher insomnia severity is linked to poorer quality of life and worse clinical outcomes in adults suffering from major depressive disorder. The data was presented at the 2021 Psych Congress, which was held in person as well as online in San Antonio, Texas.
For their study, the researchers used data from the National Health and Wellness Survey 2019. This cross-sectional survey is usually administered yearly to the general population in the U.S. The study included respondents who reported symptoms of insomnia and a major depressive disorder diagnosis in their analysis.
The researchers used generalized linear models to evaluate the association between clinical outcomes and the Insomnia Severity Index (“ISI”) score. These models were adjusted for depression severity, insurance type, alcohol use, smoking status, BMI, marital status, Charlson Comorbidity Index, ethnicity/race, sex and age.
The cohort studied was made up of more than 3,200 patients, with the researchers noting that the majority of the patients were white and about 72% of them were women. The researchers found that in regression models, a greater ISI score was linked to a higher number of emergency department and health-care provider visits in the last year as well as daytime sleepiness and higher levels of anxiety. In addition to this, a higher ISI score was linked to work impairment and poorer quality of life and activity as well as higher indirect and direct medical costs.
In their report, the researchers note that the risk for recall bias linked to self-report data from surveys and the study’s cross-sectional design were some of the research’s limitations. The results from this research show the considerable influence of insomnia on individuals suffering from major depressive disorder, with the scientists noting that insomnia also impacted health-care costs, activity, employment and health-related quality of life of an individual.
The researchers note that their results suggest that treatments for major depressive disorder that target symptoms of insomnia may improve humanistic, economic and clinical outcomes. This study was supported by Janssen Scientific Affairs LLC.
Fortunately, a number of companies, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), could soon commercialize psychedelic-based formulations whose efficacy is far greater than that of the existing mental health treatments on the market.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Major depressive disorder (“MDD”) is a medical condition that affects an individual’s behavior, mood and physical function, including sleep and appetite. This condition is sometimes referred to as clinical depression and is among the most common mental health conditions in the United States.
Insomnia is a sleep disorder that makes it hard for an individual to stay asleep, fall asleep or wake up too early. This disorder drains an individual’s mood and energy level, which affects different aspects of their lives.
A new study has found that higher insomnia severity is linked to poorer quality of life and worse clinical outcomes in adults suffering from major depressive disorder. The data was presented at the 2021 Psych Congress, which was held in person as well as online in San Antonio, Texas.
For their study, the researchers used data from the National Health and Wellness Survey 2019. This cross-sectional survey is usually administered yearly to the general population in the U.S. The study included respondents who reported symptoms of insomnia and a major depressive disorder diagnosis in their analysis.
The researchers used generalized linear models to evaluate the association between clinical outcomes and the Insomnia Severity Index (“ISI”) score. These models were adjusted for depression severity, insurance type, alcohol use, smoking status, BMI, marital status, Charlson Comorbidity Index, ethnicity/race, sex and age.
The cohort studied was made up of more than 3,200 patients, with the researchers noting that the majority of the patients were white and about 72% of them were women. The researchers found that in regression models, a greater ISI score was linked to a higher number of emergency department and health-care provider visits in the last year as well as daytime sleepiness and higher levels of anxiety. In addition to this, a higher ISI score was linked to work impairment and poorer quality of life and activity as well as higher indirect and direct medical costs.
In their report, the researchers note that the risk for recall bias linked to self-report data from surveys and the study’s cross-sectional design were some of the research’s limitations. The results from this research show the considerable influence of insomnia on individuals suffering from major depressive disorder, with the scientists noting that insomnia also impacted health-care costs, activity, employment and health-related quality of life of an individual.
The researchers note that their results suggest that treatments for major depressive disorder that target symptoms of insomnia may improve humanistic, economic and clinical outcomes. This study was supported by Janssen Scientific Affairs LLC.
Fortunately, a number of companies, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), could soon commercialize psychedelic-based formulations whose efficacy is far greater than that of the existing mental health treatments on the market.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
